致癌物质 ACSM6 会损害膀胱癌中基于 CD8+ T 细胞的免疫反应。

IF 9.5 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarker Research Pub Date : 2024-09-27 DOI:10.1186/s40364-024-00657-y

Zhenyu Nie, Bolong Liu, Jinhui Liu, Xiongbing Zu, Juanhua Wang, Jinbo Chen, Benyi Fan, Dingshan Deng

{"title":"致癌物质 ACSM6 会损害膀胱癌中基于 CD8+ T 细胞的免疫反应。","authors":"Zhenyu Nie, Bolong Liu, Jinhui Liu, Xiongbing Zu, Juanhua Wang, Jinbo Chen, Benyi Fan, Dingshan Deng","doi":"10.1186/s40364-024-00657-y","DOIUrl":null,"url":null,"abstract":"Resistance to immunotherapy in bladder cancer has greatly limited its clinical application. Through single-cell sequencing, we determined that ACSM6, an oncogene that is highly expressed in bladder cancer, promotes the abilities of proliferation, cloning, migration, and invasion. The key point is that ACSM6 can also lead to a non-inflammatory immune microenvironment by inhibiting the chemotaxis and tumor killing ability of CD8+ T cells. Survival analysis revealed that high ACSM6 expression was associated with shorter overall survival in the immunotherapy cohort. In summary, ACSM6 is expected to become a novel biomarker for predict bladder cancer progression.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"112"},"PeriodicalIF":9.5000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437728/pdf/","citationCount":"0","resultStr":"{\"title\":\"Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer.\",\"authors\":\"Zhenyu Nie, Bolong Liu, Jinhui Liu, Xiongbing Zu, Juanhua Wang, Jinbo Chen, Benyi Fan, Dingshan Deng\",\"doi\":\"10.1186/s40364-024-00657-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Resistance to immunotherapy in bladder cancer has greatly limited its clinical application. Through single-cell sequencing, we determined that ACSM6, an oncogene that is highly expressed in bladder cancer, promotes the abilities of proliferation, cloning, migration, and invasion. The key point is that ACSM6 can also lead to a non-inflammatory immune microenvironment by inhibiting the chemotaxis and tumor killing ability of CD8+ T cells. Survival analysis revealed that high ACSM6 expression was associated with shorter overall survival in the immunotherapy cohort. In summary, ACSM6 is expected to become a novel biomarker for predict bladder cancer progression.\",\"PeriodicalId\":54225,\"journal\":{\"name\":\"Biomarker Research\",\"volume\":\"12 1\",\"pages\":\"112\"},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437728/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarker Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40364-024-00657-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40364-024-00657-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

膀胱癌对免疫疗法的抗药性极大地限制了免疫疗法的临床应用。通过单细胞测序，我们确定 ACSM6 是膀胱癌中高表达的癌基因，它能促进膀胱癌的增殖、克隆、迁移和侵袭能力。关键是，ACSM6 还能通过抑制 CD8+ T 细胞的趋化和杀伤肿瘤能力，导致非炎症性免疫微环境。生存期分析表明，在免疫疗法队列中，ACSM6的高表达与较短的总生存期相关。总之，ACSM6有望成为预测膀胱癌进展的新型生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Oncogenic ACSM6 impairs CD8⁺ T cell-based immune response in bladder cancer.

Resistance to immunotherapy in bladder cancer has greatly limited its clinical application. Through single-cell sequencing, we determined that ACSM6, an oncogene that is highly expressed in bladder cancer, promotes the abilities of proliferation, cloning, migration, and invasion. The key point is that ACSM6 can also lead to a non-inflammatory immune microenvironment by inhibiting the chemotaxis and tumor killing ability of CD8⁺ T cells. Survival analysis revealed that high ACSM6 expression was associated with shorter overall survival in the immunotherapy cohort. In summary, ACSM6 is expected to become a novel biomarker for predict bladder cancer progression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarker Research Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

15.80

自引率

1.80%

发文量

审稿时长

10 weeks

期刊介绍： Biomarker Research, an open-access, peer-reviewed journal, covers all aspects of biomarker investigation. It seeks to publish original discoveries, novel concepts, commentaries, and reviews across various biomedical disciplines. The field of biomarker research has progressed significantly with the rise of personalized medicine and individual health. Biomarkers play a crucial role in drug discovery and development, as well as in disease diagnosis, treatment, prognosis, and prevention, particularly in the genome era.